STRATEGIC OUTSOURCING IN PHARMACEUTICAL INDUSTRY
Keywords:
pharmaceutical industry, outsourcing, Contract Research Organization (CRO), Big Pharma, generic companies, project management, drug developmentAbstract
The pharmaceutical industry is facing a tremendous challenge from the current global economic crisis. Enormous earnings from new “blockbuster” drugs are perishing and old drug targets are leading to limited profits. Despite substantial investment in research and development of new drugs, the return thereof is disappointing. New targets including biologic, biomarker, as well as studies of the genome, as well of drugs for treatment of chronic diseases, have much longer duration of the development phase. Therefore, companies are focused on shortening duration, lowering costs, enhancing efficiency and minimizing usage of resources. All these challenges are forcing the pharmaceutical industry to change its drug development model from a model relying on internal capacities to an open model that embodies aid from a Contract Research Organization (CRO) experienced in understanding regulatory standards, equipped with adequate infrastructure, qualified and competent staff in pharmacy, and experienced in dealing with regional issues. Outsourcing has great importance for pharmaceutical companies. Manufacturers of original pharmaceuticals may opt for outsourcing of different phases of drug development, while generic companies confide the clinical trial – the last phase of drug development – to selected CROs which meet high standards of expertise in performing the studies, using highly reliable analytical methods, located in attractive geographic locations and have competitive pricing.
This paper is inspired by the challenges with which the pharmaceutical industry has to cope in the new globalized world. At the beginning the authors provide short introduction to the significance of outsourcing in the case of the pharmaceutical industry; than differentiate Big Pharma from generic pharmaceutical companies; define benefits and risks from outsourcing in the pharmaceutical industry; stress the significance of project management as a key prerequisite of planned and executed outsourced activities; and finally present concluding remarks
References
Barthelemy, J. (2003). “The seven deadly sins of outsourcing”. Academy of management executive. Vol. 17, No. 2. Academy of Management. Briarcliff Manor, New York. p.88.
Bhatt, A. (2011). ”Quality of clinical trials: A moving target”. Perspectives in Clinical Research. Medknow Publications and Media Pvt. Ltd., Mumbai. http://www.picronline.org/text.asp?2011/2/4/124/86880
Boehm,G., Yao, L., Han. L., & Zheng, Q. (2013). “Development of the generic drug industry in the US after the Hatch_Waxman Act of 1984. Acta Pharm Sin B. pp. 297-311
Cornell Law School (2020). – Electronic code of Federal Regulations. New Drug Product Exclusivity 21 C.F.R. 314.108.
Cockburn, I. M. (2004). “The Changing Structure of the Pharmaceutical Industry”. Health Affairs. Vol.23, No.1. Project HOPE - The People-to-People Health Foundation, Inc., Milwood. pp. 10-22.
Corbett, M.F. (2004). “The Outsourcing Revolution – Why It Makes Sense and How to Do It Right”. Dearborn.
DiMasi, J. A., Hansen, R.W., & Grabowski, H. G. (2003). “Innovation in the Pharmaceutical Industry: New Estimates and R&D Costs”. Journal of Health Economics. Vol. 47. https://doi.org/10.1016/j.jhleaco.2016.01.012, pp. 26-27.
Goldenberg, N. A., Spyropoulos A. C., Halperin J. L., Kessler C. M., Schulman S., Turpie A. G., Skene, A. M, Cutler, N. R., & Hiatt, W. R. (2011). “Antithrombotic Trials Leadership and Steering Group. Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model”. Blood. American Society of Hematology, Washington D.C., pp. 2089-2092.
IQVIA Institute for Human Data Science (April, 2019). The Changing Landscape of Research and Development. https://tinyril.com/y2kpxve8. p.7.
Kesselheim, A.S., Avorn, J., & Sarpatawari, A. (2016). The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA.316 (8). PubMed & Google Scholar. pp. 858-871
Lakdawalla, D. N. (2018). “Economics of Pharmaceutical Industry”. Journal of Economic Literature. Vol.56, no.2. https://doi.org/10.1257/jel.20161327. pp. 403-404.
Maiti R., M. R. (2007). “Clinical trials in India”. Perspectives in Clinical Research. Indian Society for Clinical Research. Mumbai. http://10.4103/2229-3485.96444. pp. 1-10.
National Science Foundation (accessed February 25, 2021). “Business Enterprise Research and Development Survey” (www.nsf.gov./statistics/srvyberd/.
Noor,W., & Kleinrock, M. (2013). Pharmaceutical Executive Magazine 50.Advanstar Communications, New York, NY. pp. 20-29
OECD (2008). OECD Science, Technology and Industry Outlook 2008: Highlights. http://www.oecd.org/dataoecd/18/32/41551978.pdf. Accessed December 22, 2021. p. 3.
Pharmaceutical Research and Manufacturers of America (2020). 2020 PhRMA Annual Membership Survey. PhRMA. https://tinyurl.com/ydh6p64t. & Pharmaceutical Research and Manufacturers of America (2019). 2019 PhRMA Annual Membership Survey.https://tinyurl.com/ycneve7. pp. 1717-1737.
Sachs, G. (2004). “A New Global Pharma Outsourcing Market Model in 2007”. Praxel’s Pharmaceutical R&D Statistical Sourcebook 2004/2005. Waltham, MA: Praxel International. pp. 26-29.
Song, Y., & Barthold, D. (2018). “The Effects of State-Level Pharmacist Regulations on Generic Substitutions of Prescription Drugs”. Health Economics. Vol. 27, No. 11. https://doi.org/10.1002/hec.3796.
Thomsett, R. (2002). Radical Project Management. Prentice Hall. Upper Saddle River. New Jersey. pp. 56-64.
Zboralski, N., & Harris, A. (2001). Let your knowledge work – knowledge management in pharmaceutical development. European Pharmaceutical Contractor. SAMEDAN LTD Pharmaceutical Publisher. London. p. 93
